<DOC>
	<DOCNO>NCT00098943</DOCNO>
	<brief_summary>RATIONALE : Targeted therapy tumor necrosis factor combine fusion protein may stop growth solid tumor stop blood flow tumor . PURPOSE : This phase I trial study side effect best dose NGR-TNF treating patient advance solid tumor .</brief_summary>
	<brief_title>NGR-TNF Treating Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose-limiting toxicity maximum tolerate dose tumor vasculature-targeted tumor necrosis factor alpha ( NGR-TNF ) patient advance solid tumor . - Determine recommend phase II dose drug patient . Secondary - Determine mechanism action drug patient . - Determine response patient treated drug . OUTLINE : This open-label , nonrandomized , dose-escalation , multicenter study . Patients receive tumor vasculature-targeted tumor necrosis factor alpha ( NGR-TNF ) IV 1 hour day 1 . Courses repeat every 21 day absence unacceptable toxicity disease progression . Cohorts 1-6 patient receive escalate dos NGR-TNF maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Up 12 patient receive treatment MTD . Patients follow every 8 week disease progression start new anticancer treatment . PROJECTED ACCRUAL : A total 1-30 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis advance solid tumor amenable clinical improvement current standard treatment Preferably tumor well know angiogenic ( e.g. , renal , colon , thyroid , head neck cancer ) No clinical sign CNS involvement PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 02 OR WHO 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic Bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST and/or ALT &lt; 2.5 time ULN ( 5 time ULN presence liver metastasis ) Renal Creatinine &lt; 1.5 time ULN Cardiovascular Cardiac function normal No uncontrolled hypertension No condition hypovolemia consequence ( e.g. , increased stroke volume , elevate blood pressure ) hemodilution could represent risk patient Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No active uncontrolled systemic infection No uncontrolled disease , serious illness , medical condition would preclude study participation No know hypersensitivity/allergic reaction human albumin preparation excipients No psychological , familial , sociological , geographical condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy At least 28 day since prior immunotherapy Chemotherapy At least 28 day since prior chemotherapy recover Endocrine therapy At least 28 day since prior hormonal therapy Radiotherapy At least 28 day since prior radiotherapy recover No prior radiotherapy &gt; 25 % bone marrow reserve Surgery More 2 week since prior surgery Other No concurrent anticancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>anaplastic thyroid cancer</keyword>
	<keyword>insular thyroid cancer</keyword>
	<keyword>thyroid gland medullary carcinoma</keyword>
	<keyword>stage IV follicular thyroid cancer</keyword>
	<keyword>stage IV papillary thyroid cancer</keyword>
	<keyword>recurrent thyroid cancer</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>metastatic parathyroid cancer</keyword>
	<keyword>recurrent parathyroid cancer</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
</DOC>